Foundation Medicine, Agios developing diagnostics for cancer drugs

04/5/2013 | GenomeWeb Daily News (free registration)

Foundation Medicine and Agios Pharmaceuticals agreed to jointly develop companion diagnostics for the latter's experimental cancer drugs. The two companies will seek to identify genomic mutations to determine which patients will benefit from Agios' new cancer metabolism inhibitors that target tumors with mutated IDH1 or IDH2 metabolic enzymes.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ